GLP-1s are transforming the lives of people with diabetes and obesity by improving blood glucose control and promoting substantial weight loss. However, medication adherence is a significant challenge. US-based Vivani Medical, a clinical-stage biopharmaceutical company, is developing miniature implants which are designed to solve this problem. Once inserted, patients and caregivers can be confident that the intended medicine is being delivered throughout the once- or twice-yearly dosing...
All content for BioBiz Buzz is the property of https://biobizbuzz.com/ and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
GLP-1s are transforming the lives of people with diabetes and obesity by improving blood glucose control and promoting substantial weight loss. However, medication adherence is a significant challenge. US-based Vivani Medical, a clinical-stage biopharmaceutical company, is developing miniature implants which are designed to solve this problem. Once inserted, patients and caregivers can be confident that the intended medicine is being delivered throughout the once- or twice-yearly dosing...
2. Breaking Barriers in Sexual Health: Dicot Pharma’s LIB-01 and the Future of ED Treatment
BioBiz Buzz
14 minutes
6 months ago
2. Breaking Barriers in Sexual Health: Dicot Pharma’s LIB-01 and the Future of ED Treatment
This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide. Your host Mike Ward interviews Elin Trampe, CEO of Dicot Pharma, who discusses the company’s innovative drug candidate, LIB-01. Unlike conventional therapies, LIB-01 introduces a novel mechanism of action and offers a significantly longer efficacy window, 28 days after a brief 3-day dosing accor...
BioBiz Buzz
GLP-1s are transforming the lives of people with diabetes and obesity by improving blood glucose control and promoting substantial weight loss. However, medication adherence is a significant challenge. US-based Vivani Medical, a clinical-stage biopharmaceutical company, is developing miniature implants which are designed to solve this problem. Once inserted, patients and caregivers can be confident that the intended medicine is being delivered throughout the once- or twice-yearly dosing...
